前列腺癌主动监测是否已变得更安全?来自全球临床注册研究的经验教训
该研究基于国际数据库2000年起25个队列15个国家26 999名主动监测(AS)男性的数据,重点分析14 623名随访超过6年的低危或选择性的中危前列腺癌患者。结果显示10年总生存率84.1%、无转移生存率99.4%,初始低危者10年治疗概率20%、中危者31%,作者认为AS是安全的管理选择。
要点
- 在2000-2016年四个4年时间段内,总生存无显著变化,无转移生存率自第二时间段起改善且超过99%。
- 10年总生存率84.1%,10年无转移生存率99.4%。
- 初始低危肿瘤者10年治疗概率20%,中危肿瘤者31%。
核心结论
- 作者认为,在这项长期随访的大样本多中心队列中,主动监测在整个随访期间是安全的管理选择。
研究设计与样本
- 国际数据库自2000年起收集15个国家25个队列共26 999名主动监测男性的临床数据。
- 重点报告14 623名低危或选择性中危前列腺癌男性、随访超过6年的安全性和可接受性及治疗结局。
主要发现
- 在预设的四个4年时间段(覆盖2000-2016年)内,总生存无显著变化,无转移生存率自第二时间段起改善且超过99%。
- 较早时间段的免治疗生存率显示稍快地转向根治性治疗。
- 焦虑作为治疗更改原因的比例始终为5%;10-15%的治疗更改无明确原因;10-15%的男性以肿瘤进展为治疗触发因素。
- 选择根治性治疗的男性中,手术是最常见治疗方式;接受根治性治疗者中90%在治疗后5年无生化复发。
- 10年总生存率84.1%,10年无转移生存率99.4%;初始低危肿瘤者10年治疗概率20%,中危肿瘤者31%。
关键数值与推荐
- 10年总生存率84.1%,10年无转移生存率99.4%。
- 初始低危肿瘤者10年治疗概率20%,中危肿瘤者31%。
- 接受根治性治疗者中90%在治疗后5年无生化复发。
- 焦虑作为治疗更改原因的比例为5%;10-15%的治疗更改无明确原因;10-15%以肿瘤进展为治疗触发因素。
临床怎么用
- 作者认为,新的诊断方法可能通过个体化风险评估改善随访的可接受性,同时安全地扩大主动监测在较高危肿瘤中的应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Active surveillance (AS) has evolved into a widely applied treatment strategy for many men around the world with low-risk prostate cancer (or in selected cases intermediate-risk disease). Here, we report on the safety and acceptability of AS, and treatment outcomes for low- and intermediate-risk tumours over time in 14 623 men with follow-up of over 6 yr. METHODS: Clinical data from 26 999 men on AS from 25 cohorts in 15 countries have been collected in an international database from 2000 onwards. KEY FINDINGS AND LIMITATIONS: Across our predefined four time periods of 4 yr each (covering the period 2000-2016), there was no significant change in overall survival (OS). However, metastasis-free survival (MFS) rates have improved since the second period and were excellent (>99%). Treatment-free survival rates for earlier periods showed a slightly more rapid shift to radical treatment. Over time, there was a constant proportion of 5% of men for whom anxiety was registered as the reason for treatment alteration. There was, however, also a subset of 10-15% in whom treatment was changed, for which no apparent reason was available. In a subset of men (10-15%), tumour progression was the trigger for treatment. In men who opted for radical treatment, surgery was the most common treatment modality. In those men who underwent radical treatment, 90% were free from biochemical recurrence at 5 yr after treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study confirms that AS was a safe management option over the full duration in this large multicentre cohort with long-term follow-up, given the 84.1% OS and 99.4% MFS at 10 yr. The probability of treatment at 10 yr was 20% in men with initial low-risk tumours and 31% in men with intermediate-risk tumours. New diagnostic modalities may improve the acceptability of follow-up using individual risk assessments, while safely broadening the use of AS in higher-risk tumours. PATIENT SUMMARY: Active surveillance (AS) has evolved into a widely applied treatment strategy for many men with prostate cancer around the world. In this report, we show the long-term safety of following AS for men with low- and intermediate-risk prostate cancer. Our study confirms AS as a safe management option for low- and intermediate-risk prostate cancer. New diagnostic modalities may improve the acceptability of follow-up using individual risk assessments, while safely broadening the use of AS in higher-risk tumours.
引用
- Bangma C, Doan P, Zhu L, et al. Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. Eur Urol Oncol. 2024. PMID: 39025687. doi:10.1016/j.euo.2024.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。